key: cord-0027282-dbnqbrab authors: Köllner, Sarah M. S.; Seifert, Larissa; Zahner, Gunther; Tomas, Nicola M. title: Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy date: 2022-02-03 journal: Front Immunol DOI: 10.3389/fimmu.2022.822508 sha: 86b38ad7d741d9dc752c14ecb3291b6782aa6755 doc_id: 27282 cord_uid: dbnqbrab Membranous nephropathy (MN) is a rare but potentially severe autoimmune disease and a major cause of nephrotic syndrome in adults. Traditional treatments for patients with MN include steroids with alkylating agents such as cyclophosphamide or calcineurin inhibitors such as cyclosporine, which have an undesirable side effect profile. Newer therapies like rituximab, although superior to cyclosporine in maintaining disease remission, do not only affect pathogenic B or plasma cells, but also inhibit the production of protective antibodies and therefore the ability to fend off foreign organisms and to respond to vaccination. These are undesired effects of general B or plasma cell-targeted treatments. The discovery of several autoantigens in patients with MN offers the great opportunity for more specific treatment approaches. Indeed, such treatments were recently developed for other autoimmune diseases and tested in different preclinical models, and some are about to jump to clinical practice. As such treatments have enormous potential to enhance specificity, efficacy and compatibility also for MN, we will discuss two promising strategies in this perspective: The elimination of pathogenic antibodies through endogenous degradation systems and the depletion of pathogenic B cells through chimeric autoantibody receptor T cells. Membranous nephropathy (MN) is a rare but potentially severe kidney disease and a major cause of nephrotic syndrome in adults. According to the new KDIGO 2021 Clinical Practice Guidelines, a nephrotic syndrome is defined as proteinuria of more than 3.5 grams per 24 hours or a protein-tocreatinine ratio of more than 3 g/g in combination with low plasma albumin, peripheral edema, and hyperlipidemia (1) . The descriptive term "membranous" refers to the prominent change that is classically seen in light microscopy: a diffuse thickening of the glomerular basement membrane (2) . Additionally, granular depositions of immunoglobulins and complement components can be detected by immunofluorescence microscopy, suggesting a role of both autoantibodies and the complement system in the pathogenesis of MN. The hallmark findings in electron microscopy include electron-dense deposits in a subepithelial localization, i.e. on the outer aspect of the glomerular basement membrane (GBM), and an extensive effacement of podocyte foot processes. Due to the prominent glomerular IgG positivity in biopsies of affected patients, MN has long been assumed to be an antibodymediated autoimmune disease. The discoveries of several target antigens for circulating autoantibodies in MN patients in the past decade has corroborated this assumption. These targets include neutral endopeptidase (NEP) (3), M-type phospholipase A2 receptor (PLA2R1) (4), thrombospondin type-1 domaincontaining protein 7A (THSD7A) (5) , neural epidermal growth factor-like 1 protein (NELL-1) (6), semaphorin 3B (SEMA3B) (7), protocadherin 7 (PCDH7) (8) , NCAM1 (9) and HTRA1 (10) . PLA2R1-associated MN is diagnosed in around 70% of cases and thus represents the most common MN sub-entity. The current view on the pathogenesis of MN ( Figure 1 ) is that predisposing factors, such as an underlying genetic disposition and/or immune dysregulation, in combination with an initiating trigger such as an infection, a malignancy or environmental factors lead to loss of tolerance for the respective autoantigen with consecutive activation of B cells and production of autoantibodies (11) (12) (13) (14) (15) (16) (17) (18) . B cells differentiate towards plasma and/or memory B cells, which in turn produce large amounts of autoantibodies. These autoantibodies reach the kidney via the circulation and bind to their target antigen, which is assumed to induce damage to podocytes with subsequent loss of plasma proteins to the urine, likely via complementdependent and complement-independent mechanisms (19) . Complement-independent mechanisms have been ill-defined so far, but may include modification of cellular signaling, antigen/receptor blocking or stimulation or interference with the antigens' biological function, e.g. enzymatic activity. Importantly, the direct pathogenicity of autoantibodies has been demonstrated by transfer experiments of patient-derived anti-NEP and anti-THSD7A autoantibodies, which cause MN in animals (3, 20) . Even though such a mechanism has not been demonstrated for anti-PLA2R1 autoantibodies, the association of high autoantibody levels with an unfavorable clinical outcome in patients with PLA2R1-associated MN and the development of MN transgenic mice expressing the murine PLA2R1 after transfer of rabbit anti-PLA2R1 antibodies strongly argue for a pathogenic role of anti-PLA2R1 autoantibodies (21, 22) . Alternative proposed mechanisms of immune deposit formation in MN include glomerular deposition of preformed immune complexes and binding of circulating antibodies to a planted antigen (23, 24) , but the relevance of these mechanisms is less clear. FIGURE 1 | Current view on the pathogenesis of membranous nephropathy and potential targets for antigen-specific treatments. Predisposing factors such as underlying genetic dispositions and/or immune dysregulation in combination with an initiating trigger such as an infection, a malignancy or environmental factors may lead to loss of tolerance for the respective autoantigen with consecutive activation of B cells and production of autoantibodies. B cells differentiate to plasma and/or memory B cells, which in turn produce large amounts of autoantibodies. These autoantibodies reach the kidney via the circulation and bind to their target antigen (e.g. PLA2R1 or THSD7A), which induces damage to podocytes with subsequent urinary loss of plasma proteins. Complement-dependent and complementindependent injury mechanisms are likely to be involved. Depletion of autoantibody-producing B cells or elimination of pathogenic autoantibodies constitute potential antigen-specific treatments for MN. The clinical outcome in patients with MN is highly variable with about one-third of patients experiencing spontaneous remission within one year after diagnosis, whereas another 20-30% develop end-stage renal disease within 10 years (25) . The identification of patients with an unfavorable outcome, which would benefit from early immunosuppressive treatment, represents a major clinical challenge. Classical treatment regimens for MN include the use of steroids in combination with alkylating agents or calcineurin inhibitors (26) (27) (28) (29) . Recently, two large prospective clinical trials have investigated the use of rituximab in the treatment for MN. The MENTOR trial compared rituximab with cyclosporine and found rituximab to be superior to cyclosporine in maintaining remission for up to 24 months (30) . The RI-CYCLO trial found comparable remission rates with the use of rituximab and cyclophosphamide and no significant differences in the safety profiles of these medications (31) . The novel KDIGO guidelines define clusters of patients according to the risk of disease progression and loss of renal function. Categories comprise low risk, moderate risk, high risk, and very high risk, depending on proteinuria, serum albumin, estimated GFR (eGFR), and anti-PLA2R1 antibody levels (1). Patients with a low or moderate risk of disease progression are usually treated with optimal supportive care (e.g. antiproteinuric therapy with renin-angiotensin aldosterone system inhibition (RAAS) and blood pressure control) and monitored for 3-6 months. In case of worsening proteinuria, eGFR or antibody levels, patients should be evaluated for treatment with rituximab or calcineurin inhibitors. Patients with a high risk of disease progression should be treated with rituximab or cyclophosphamide plus steroids or a calcineurin inhibitor plus rituximab and patients with a very high risk should receive cyclophosphamide plus steroids (1). While calcinerin inhibitors and cyclophosphamide are broad immunosuppressants, rituximab is targeting B cells expressing the surface marker CD20. Initially developed as a lymphoma treatment, it acts through different mechanisms of action: i) Antibody-dependent cellular cytotoxicity (ADCC) through either NK cells, monocytes or granulocytes (32-34) (ii) apoptosis of B cells through caspase 3 activation (35) and iii) complement-dependent cytotoxicity (36, 37) . In summary, the targets of autoimmunity in MN have been increasingly understood and therapies have shifted from broad immunosuppression using alkylating agents and calcineurin inhibitors towards a more pathogenesis-based treatment targeting autoantibody-producing B cells using rituximab. However, rituximab treatment may entail resistance towards apoptosis, ADCC, CDC and downregulation or loss of CD20 (38) , which can decrease treatment efficacy. It also affects preexisting protective antibodies, reduces the body's ability to generate an immune response against foreign organisms, and greatly decreases the response to vaccination. These are undesired effects of B cell-targeted treatments, in particular in the setting of a worldwide pandemic (39) , and may limit the use of agents such as rituximab in the treatment of antibodymediated diseases. Additionally, the increasing knowledge on specific antigens in MN principally enables antigen-specific treatment strategies, which would ideally target the immunological disease mechanisms while sparing protective immunity. Such antigen-specific therapies would have enormous potential to enhance specificity, efficacy and compatibility. Hence, there is a considerable gap between the increasing knowledge on the pathogenic role of autoantibodies and autoantigens in MN on the one side and the currently available treatments with limited specificity on the other side. In the following, we will discuss two promising strategies that could be applied in the field of MN: The elimination of pathogenic antibodies through endogenous degradation systems and the elimination of autoreactive B cells through chimeric autoantibody receptor T cells (Figure 1 ). Physiologically, immunoglobulins (IgG) are constantly taken up by endothelial cells and shuttled to the sorting endosome. At pH 6 inside the sorting endosome IgG binds to the neonatal Fc receptor (FcRn) and is transported to the cell surface. Now at pH 7.4 the IgG is released from the FcRn back into the circulation due to a reduced affinity at neutral pH. This system prolongs the half-life of IgG in the circulation to approximately 30 days (40) . Consequently, antibodies may also prolong the half-life of their target antigen by constant recirculation from endothelial cells back to the plasma. Sweeping antibodies as potential therapeutics to remove soluble antigens from plasma were first described by Igawa et al. (41) . Sweeping antibodies are engineered IgG that remove soluble antigens from the circulation, which is enabled by two distinct modifications: a pH-dependent binding to the antigen and an increased affinity of the antibody Fc part to an Fc receptor (FcR) (41) . A pH-dependent antigen binding can be achieved by histidine mutagenesis, meaning that amino acids in the Fab region of the antibody are substituted for histidines. In the acidic environment of the sorting endosome, the protonated histidines lead to conformational changes in the Fab region of the sweeping antibody, which results in weakening of the binding to the antigen and finally dissociation of antibody and antigen. Enhanced immune complex uptake into the endosome is achieved by mutations in the Fc region, increasing the binding to either FcRn or FcgRIIB. After injection, a sweeping antibody binds its target molecule in the circulation. The resulting immune complex is then taken up into endothelial cells by pinocytosis or FcR-mediated endocytosis. In the sorting endosome, the pH shifts from neutral to slightly acidic (pH 6) and the antigen is released from the sweeping antibody. While the sweeping antibodybound by the FcRnis shuttled to the cell surface and released there, the antigen is degraded in the lysosome. The enhanced affinity to the FcR allows efficient recirculation of the therapeutic sweeping antibody from endothelial cells to the plasma, which in turn leads to further removal of antigens from the circulation, creating the "sweeping" effect. Several different mutations have been described that enhance active internalization of antigenantibody complexes via FcRn, leading to efficient degradation of the antigen (42) (43) (44) . Sweeping can also occur through the FcgRIIB (45) . FcgRIIB is the only inhibitory Fc receptor with an immunoreceptor-based inhibitory motif (ITIM) and normally has a very low affinity for IgG monomers (IgG1